Physician profile
Omar Perez
NPI 1043393465
$977.43
in general payments reported to CMS, 2019-2025
15 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $28.57 · 2021: $61.59 · 2022: $277 · 2023: $212 · 2024: $32.53 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $375.16 | 2021-2023 | Farxiga |
| Pfizer INC. | $183.97 | 2019-2023 | |
| Astellas Pharma US INC | $131.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.57 | 2022-2025 | |
| Depuy Synthes Sales INC. | $38.37 | 2025 | Cerepak Uniform |
| Boston Scientific Corporation | $28.95 | 2024-2025 | Ekosonic, General - Pain Management |
| Pbg Puerto Rico LLC | $28.57 | 2020 | |
| Cipher Pharmaceuticals US LLC | $24.56 | 2025 | Spinosad, Natroba |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.74 | 2022 | |
| Mannkind Corporation | $15.62 | 2019 | |
| Pfizer Pharmaceuticals LLC | $13.81 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.58 | 2019 | |
| Merck Sharp & Dohme LLC | $11.51 | 2019 | |
| Glaxosmithkline, LLC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.